PRGO up +0.54% percent Today $PRGO High is at 155.77 and

New Post Public Reply Private Reply Replies (0) Message Board
Lucky Jimmy
PRGO up +0.54% percent Today $PRGO High is at 155.77 and the Low 154.27 with current volume of 145,960.

Recent News posted below.

Perrigo Company PRGO other info.
http://investorshangout.com/Perrigo-Company-PRGO-55158/

PRGO Perrigo Company Recent Headline News

Survey Finds Infant Feeding Tops List of Questions New Parents Ask Pediatricians
PR Newswire - Thu Nov 13, 7:50AM CST
New parents often have an endless list of questions about caring for their little ones, and the pediatrician serves as a go-to resource for everything from nutritional needs to serving as a sounding board for surreal questions (Is it Okay to Take My Newborn Kite Surfing?), according to a new survey. Perrigo Nutritionals, makers of Store Brand Formula, today released findings from its nationwide "Pulse of Pediatricians" survey*--conducted by SERMO, the largest online network exclusively for physicians--and found that pediatricians rank feeding (52 percent), pooping (43 percent), and sleeping (41 percent) as the top three categories of concern for new parents. In fact, 97 percent of pediatricians say questions around feeding falls in the top three for their patients.
PRGO: 155.50 (+0.63)

Tracking The Parnassus Core Equity Fund
IVI Guy - at Seeking Alpha - Wed Nov 12, 6:45AM CST

WDFC: 77.98 (+0.17), SJR: 26.16 (-0.04), PRGO: 155.50 (+0.63), XYL: 37.52 (-0.03), CHRW: 72.95 (+0.09), MDLZ: 37.92 (unch), MKC: 73.28 (+0.05), MDU: 25.15 (-0.27), SYY: 38.70 (-0.24), PDCO: 45.77 (+0.64), PNR: 68.56 (+0.12), TRI: 38.08 (-0.16), UPS: 108.30 (-0.32), PEP: 98.03 (+0.87), AGN: 196.57 (+0.06), MSI: 64.35 (+0.65), NOV: 70.88 (-2.12), NWN: 47.01 (-0.08), EGN: 66.77 (-1.93), EBAY: 54.41 (+0.35), QCOM: 70.58 (+0.29), AMAT: 22.82 (+0.33), ACN: 84.30 (+0.18), AAPL: 113.09 (+1.84), MA: 84.25 (-0.10), SCHW: 28.71 (-0.07), STR: 23.85 (-0.09), SE: 38.00 (-0.96), GAS: 51.88 (-0.24), IRM: 38.20 (+0.15), WM: 49.37 (-0.01), CMP: 88.88 (+0.19), VRSK: 62.95 (-0.17), GILD: 104.90 (-2.00), EXPD: 43.89 (-0.02), TFX: 114.76 (+0.29), CVS: 89.90 (+0.61), PG: 88.90 (-0.58), PX: 126.19 (-0.04), NVS: 94.40 (+1.74)

Dividend Contenders, Future Champions Or Future Failures: Part 6
Stan Stafford - at Seeking Alpha - Fri Nov 07, 5:13PM CST

PRGO: 155.50 (+0.63), NVO: 44.01 (-0.31), CAH: 80.89 (+0.65), TEVA: 57.66 (-0.78)

Perrigo to re-launch the expectorant tablets Guaifenesin Extended-Release 600mg in the US
M2 - Fri Nov 07, 6:22AM CST
Healthcare company Perrigo Company (NYSE RGO) said on Thursday that it has re-initiated shipments of Guaifenesin 600mg Extended-Release tablets to its retail and wholesale customers in the US.
PRGO: 155.50 (+0.63)

Perrigo Public Limited's (PRGO) CEO Joseph Papa on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 07, 6:10AM CST

PRGO: 155.50 (+0.63)

Perrigo to buy Omega Pharma
at Investor's Business Daily - Thu Nov 06, 5:49PM CST
The Ireland-based pharmaceuticals maker agreed to buy Belgium-based Omega Pharma for $4.5 bil, including debt, in a deal designed to expand Perrigo's (PRGO) presence in Europe. In its fiscal Q1, Perrigo earned $1.40 a share, missing views by 4 cents,...
PRGO: 155.50 (+0.63)

After Yesterday's Decline of 3.79%, Perrigo Offers Investors Better Value
Comtex SmarTrend(R) - Thu Nov 06, 3:41PM CST
Perrigo (NASDAQ RGO) traded in a range yesterday that spanned from a low of $145.41 to a high of $160.85. Yesterday, the shares fell 3.8%, which took the trading range below the 3-day low of $158.30 on volume of 4.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
PRGO: 155.50 (+0.63)

Perrigo (PRGO) Earnings Report: Q1 2015 Conference Call Transcript
at The Street - Thu Nov 06, 3:39PM CST
The following Perrigo (PRGO) conference call took place on November 6, 2014, 10:00 AM ET. This is a transcript of that earnings call:
PRGO: 155.50 (+0.63)

Perrigo Misses on Earnings and Sales, Maintains Guidance - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 10:08AM CST
Perrigo Companys reported first-quarter fiscal 2015 earnings of $1.40 per share.
AGN: 196.57 (+0.06), BIIB: 318.01 (-3.01), PRGO: 155.50 (+0.63), ABBV: 63.81 (+0.05)

Today's Market: Earnings And News Moving These 5 Stocks
Matthew Smith - at Seeking Alpha - Thu Nov 06, 9:01AM CST

TSLA: 254.77 (+5.67), PRGO: 155.50 (+0.63), QCOM: 70.57 (+0.28), AZN: 74.64 (+0.38), SNY: 46.54 (-0.02)

Perrigo buys consumer health products firm
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 6:44AM CST

PRGO: 155.50 (+0.63)

Perrigo Reinitiates Shipments Of Guaifenesin Extended-Release 600mg Tablets, The Store Brand Equivalent To Mucinex® 600mg Extended-Release Tablets
PR Newswire - Thu Nov 06, 5:39AM CST
Perrigo Company plc (NYSE: PRGO; TASE) announced today that it has reinitiated shipments of Guaifenesin 600mg Extended-Release tablets to its retail and wholesale customers in the United States. The product will be packaged and marketed under store and proprietary brands and will be a high quality, value alternative to Mucinex® 600mg Extended-Release tablets.
PRGO: 155.50 (+0.63)

Perrigo misses by $0.04, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 5:35AM CST

PRGO: 155.50 (+0.63)

Perrigo Company PLC Reports Record First Quarter Revenue, Adjusted Net Income And Adjusted Margins
PR Newswire - Thu Nov 06, 5:32AM CST
-- Fiscal first quarter net sales increased to a first quarter record of $952 million.
PRGO: 155.50 (+0.63)

Perrigo Company plc To Acquire Omega Pharma NV For EUR 3.6 Billion Creating A Top Five Global OTC Company
PR Newswire - Thu Nov 06, 5:26AM CST
Perrigo Company plc (NYSE: PRGO; TASE), a leading global provider of "Quality Affordable Healthcare Products®," and Omega Pharma NV, one of the largest OTC healthcare companies in Europe, headquartered in Nazareth, Belgium, today announced that they have entered into a definitive agreement in which Perrigo has agreed to acquire Omega for EUR 3.6 billion, or $4.5 billion, comprised of the purchase of Omega's equity for EUR 2.48 billion and the assumption of EUR 1.1 billion in debt. The transaction, funded through a combination of cash, debt, and equity, will enhance Perrigo's leading OTC product offering and expand its distribution through Omega's strong established platform.
PRGO: 155.50 (+0.63)

Will Perrigo (PRGO) Disappoint This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 04, 3:45PM CST
Perrigo (PRGO), which is scheduled to report first-quarter fiscal 2015 results on Nov 6, had delivered a positive earnings surprise of 12.26%.
MDVN: 107.39 (+1.06), ACT: 242.04 (+1.42), PRGO: 155.50 (+0.63), ALNY: 101.36 (+1.51)

Financial Results, Appointments, and Upcoming Conference Calls - Research Reports on Yelp, Vantiv, Discovery, Vistaprint and Perrigo
PR Newswire - Tue Nov 04, 7:55AM CST
Today, Analysts Review released its research reports regarding Yelp, Inc. (NYSE: YELP), Vantiv, Inc. (NYSE: VNTV), Discovery Communications, Inc. (NASDAQ: DISCA), Vistaprint N.V. (NASDAQ: VPRT) and Perrigo Company Plc (NYSE: PRGO). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7669-100free.
PRGO: 155.50 (+0.63), DISCA: 32.70 (+0.84), VPRT: 67.20 (-1.18), VNTV: 31.03 (+0.13), YELP: 58.58 (-2.00)

Perrigo declares $0.105 dividend
Seeking Alpha - at Seeking Alpha - Mon Nov 03, 2:44PM CST

PRGO: 155.50 (+0.63)

Perrigo Company plc Announces Quarterly Dividend
PR Newswire - Mon Nov 03, 2:12PM CST
Perrigo Company plc (NYSE: PRGO;TASE) today announced that its Board of Directors declared a quarterly dividend of $0.105 per share, payable on December 16, 2014 to shareholders of record on November 28, 2014.
PRGO: 155.50 (+0.63)

Perrigo Rises 4.08% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Oct 30, 4:18PM CDT
Perrigo (NASDAQ RGO) traded in a range yesterday that spanned from a low of $153.00 to a high of $161.35. Yesterday, the shares gained 4.1%, which took the trading range above the 3-day high of $156.35 on volume of 1.1 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
PRGO: 155.50 (+0.63)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Swanson Nexus Pro Launch: Boost for Dietitians

Updated Category News Views 195

Swanson Enters the Education Arena for Nutritionists Swanson Vitamins is mixing things up again! This time, they're launching something called Swanson Vitamins Nexus Pro, aimed squarely at the registered dietitians and licensed nutritionists crowd. Starting out as the place to grab your basic vitamins, Swanson's not resting on their supplement laurels. No, siree. They've...

Continue Reading
Wenda Pharma's NHWD-870 HCl Shows Promise in Trial

Updated Category News Views 266

Breaking Through in NUT Carcinoma Treatment Imagine battling an aggressive disease with barely any options left, and then something hopeful shows up in the pipeline. That's the story with Zhejiang Wenda Pharma's NHWD-870 HCl, an oral BET inhibitor making waves at the 2026 ESMO Annual Meeting. Facing off against the nasty beast that is NUT carcinoma, this drug didn't just...

Continue Reading
ASTS Faces Crucial Deadline Amidst Legal Turmoil

Updated Category News Views 208

Ah, the ticking clock in the world of stock investments, where a nifty little thing called a class action lawsuit can flip your investment on its head. Right now, AST SpaceMobile (NASDAQ: ASTS) investors are staring down the barrel of one such lawsuit. With the November 13, 2026, deadline looming, it's time to sort the facts from the muck. Pins and Needles for ASTS...

Continue Reading
Kelun-Biotech's Sacituzumab Tirumotecan Shows Promise in NSCLC

Updated Category News Views 33

Kelun-Biotech's Recent Breakthrough Grab your coffee, and let's chat about something that might just change the lung cancer treatment game: Kelun-Biotech's sacituzumab tirumotecan, or sac-TMT, showing some serious promise in a Phase III trial. With numbers that could make any investor sit up a little straighter, this study has turned heads at the European Society for...

Continue Reading
Borr Drilling's Rig Sinks, Uncertainty Looms Offshore

Updated Category News Views 0

Unexpected Turn of Events at Sea Now here's a gut-punch nobody saw coming. Borr Drilling Limited (NYSE and OSE: BORR) got hit hard when their Prospector 5 drilling rig went under the waves offshore Gabon. This ain't no desk job dilemma; we're talking about a real-life offshore catastrophe. It all went down on October 24, 2026, when the rig experienced a punch through...

Continue Reading
Innovent's IBI3001 Shows Promise in Phase 1 Trials

Updated Category News Views 164

Pioneering Path with IBI3001 at ESMO 2026 Navigating through the crowded landscape of oncology trials, Innovent Biologics recently rolled out some riveting Phase 1 clinical data for their new darling, IBI3001. Top brass from Innovent took to the European Society for Medical Oncology (ESMO) Congress stage to lay bare their findings. Obviously, when you're presenting a...

Continue Reading
Axon Body 5: A Leap Forward in AI for Public Safety

Updated Category News Views 284

Axon Raises the Stakes with Body 5 Camera Boy, oh boy, Axon's dropped a bombshell with the Body 5. We're talking a colossal leap into the AI era for public safety, and if you're in the biz, you can't just shrug this one off. We're looking at 25 times the AI processing power compared to Axon's old units. That's right, I said twenty-five. Real-time situational awareness in...

Continue Reading
Spooky Dining at CARNE: A Halloween Hit in Oxnard

Updated Category News Views 242

A Festive Transformation at CARNE Rolling into Oxnard, you're met with an unconventional dining spectacle at CARNE. It's not your average restaurant fare as they've pulled out the stops with their spirited Halloween pop-up, A Nightmare at CARNE. Channeling the eerie charm of "The Nightmare Before Christmas," this temporary transformation morphs the venue into a lively,...

Continue Reading
Alaska's Insurance Maze: Coverage Over Cheap Policies

Updated Category News Views 171

Beyond Premiums: Assessing Real Coverage Needs The Alaskan wilderness isn't just home to stunning views; it's also a land where insurance needs to go beyond the average cookie-cutter policy. You'd think the cheapest option would suffice, but that's where residents might trip into financial quicksand. Devery Prince, a seasoned insurance principal, sheds light on why...

Continue Reading
World Young Scientist Summit 2026 in Wenzhou Kicks Off

Updated Category News Views 208

Young Minds Meet AI Innovation Crack open the playbook, and it's clear: young brains from across the globe are gathering in Wenzhou, Zhejiang, China, to wrangle with AI and chart the course of science toward a sustainable future. The World Young Scientist Summit 2026 isn't just a parade of speeches and accolades. Nah, it's a deep dive into where innovative minds believe...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring Precious Metals and Energy Investors' Strategies

Updated Category News Views 143

Current Trends in Precious Metals The appeal of precious metals like gold and silver continues to gather momentum, particularly in light of recent global events. Many analysts believe that geopolitical tensions have created a catalyst for increased interest in gold as a safe haven. As governments grapple with economic challenges, investors are keenly observing changes in...

Continue Reading
Understanding P/E Ratios in the Context of Casey's General Stores

Updated Category News Views 175

Analyzing P/E Ratios for Investment Decisions In today’s market, understanding the performance metrics of stocks is vital. Currently, Casey's General Stores Inc. (NASDAQ: CASY) is noted at an impressive share price of $536.66. This reflects a modest increase of 0.33%. In examining market trends, the past month saw a slight decline of 4.39% in share value. However,...

Continue Reading
China's New Lending Outlook: Economic Recovery Strategies

Updated Category News Views 135

China's Recent New Lending Trends Recent updates reveal a significant rise in new bank lending in China. However, it didn't quite meet expectations, as analysts had hoped for a stronger performance. After disappointing figures in July, which hit a 15-year low, new data shows that Chinese banks issued around 900 billion yuan (approximately $126.86 billion) in new loans in...

Continue Reading
ParkOhio Shares Important Quarterly Dividend News for Investors

Updated Category News Views 177

ParkOhio Holdings Announces Latest Dividend Declaration Park-Ohio Holdings Corp. (NASDAQ: PKOH) recently declared a significant quarterly cash dividend of $0.125 per share to its common stockholders. This distribution demonstrates the company's ongoing commitment to providing returns to its shareholders. This dividend will be payable soon, marking another positive...

Continue Reading
Investigation Launched for Tourmaline Bio's Shareholders

Updated Category News Views 259

Investigation Overview on Tourmaline Bio, Inc. Recently, Monteverde & Associates PC, a renowned law firm, has initiated an investigation concerning Tourmaline Bio, Inc. (NASDAQ: TRML) and its proposed sale to Novartis AG. This potential acquisition raises several questions about the fairness of the deal, specifically regarding the cash payment offered to shareholders....

Continue Reading